ChronoScale Holdings Corporation (CHRN) is an accelerated-compute provider that builds and operates GPU capacity for artificial intelligence workloads. Formed in May 2026 when Applied Digital combined its cloud business with Ekso Bionics, the Menlo Park–based company sells dedicated AI infrastructure to frontier labs and enterprise customers. Shortly after the opening bell on Nov. 19, the stock traded at $9.90, up 3.45% from the prior session's close of $9.57 — a confirmed advance. No new company release or filing drove the move. The gain tracked a powerful rally across AI hardware and infrastructure names, with shares also stabilizing after a sharp post-financing selloff.
The dominant force behind the session was sector beta. Technology leadership was broad and decisive: the benchmark technology sector exchange-traded fund climbed roughly 3.0%, Nvidia (NVDA) rose 4.0%, Super Micro Computer (SMCI) gained 4.4%, and Applied Digital (APLD) — ChronoScale's controlling shareholder — advanced 7.5%. When the AI compute supply chain trades as a single factor, a GPU-capacity landlord such as CHRN is pulled along with it. Notably, ChronoScale lagged its parent and its server-building peer, a pattern consistent with company-specific overhangs still weighing on the shares rather than fresh enthusiasm.
ChronoScale's largest fundamental development remains the Nov. 18 announcement of definitive agreements for a 50/50 development partnership with STN, Inc. on a data center campus in Odessa, Texas. A frontier AI lab ordered the first 65 megawatts, slated for deployment in the first half of 2027, carrying total contract value of up to $7.5 billion over six years, with a substantial portion backstopped by credit support from an investment-grade technology company. ChronoScale holds a right of first offer on the remaining 285 megawatts.
The same release disclosed up to $750 million of financing: $153 million of common stock sold at $8.00 per share — roughly 18% below the prior close — a $97 million convertible note from Applied Digital converting at the same price, and an up to $500 million convertible preferred facility with a $12 minimum conversion price. Shares initially sold off on the dilution, which approaches 27% before any preferred conversion, before stabilizing. Today's modest advance is best read as partial recovery from that reaction rather than a fresh re-rating.
Average daily volume is roughly 200,000 shares, and the Nov. 18 session traded heavier than usual at about 263,000 shares with a wide $8.18–$9.90 range. Volume in the opening minutes of Nov. 19 was light, so the early percentage change reflects thin early-session liquidity rather than a decisive institutional bid. The advance was smaller than the technology sector's gain, showing divergence from — not leadership of — the group. Technically, the stock remains far below its 30-day and 100-day moving averages and about 67% under its 52-week high of $30.00, while holding above the $8.00 private placement price, a level the market is treating as near-term support.
The score measures two things on a 0-to-100 scale: how material the verified news is, and how unusual the price move is for the stock. A 0 means no meaningful news and a routine move; 100 means transformative news and an extreme, rare move. CHRN scores 18 out of 100.
The verified news is genuinely substantial in isolation — a six-year agreement worth up to $7.5 billion for a half-owned venture, plus up to $750 million of financing, against a market capitalization near $1.4 billion. But it was published on Nov. 18, drew a negative first response on dilution, and is now being absorbed rather than discovered. The price move is unremarkable: at 3.45%, it is roughly two-thirds of the stock's average absolute daily move of about 5.3% over the last 60 sessions, and moves of that size or larger occurred 38 times in that window. Strong-but-stale news plus an ordinary move produces a low score.
The fiscal second quarter ends Nov. 30, 2026, putting the next earnings report in the December–January window; investors will focus on cash burn, customer prepayments and whether contracted revenue continues converting into signed, financed capacity. Near-term catalysts include expiration of the Hart-Scott-Rodino waiting period for the partnership, closing conditions and financing for the Odessa build, and shareholder approval mechanics for Applied Digital's note conversion. The preferred facility requires a five-day volume-weighted price of at least 110% of the $12 floor — about $13.20 — before draws, so most of that capital is currently out of reach. Risks include a going-concern disclosure tied to a working-capital deficit, heavy purchase obligations for AI hardware, execution on construction timelines, dependence on a single unidentified customer, and further dilution.
Tickeron's Trending AI Robots page highlights the automated strategies performing best in current market conditions, drawn from a library of hundreds of AI trading bots covering thousands of tickers. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, and only a curated selection earns a place in this trending section. For readers tracking volatile AI-infrastructure names, it offers a structured way to compare live strategies against the broader universe. Explore the page to see which bots are leading right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CHRN saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In 76 of the 82 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CHRN turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 43 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CHRN entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CHRN's RSI Indicator exited the oversold zone, 29 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +14.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRN advanced for three days, in 239 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
CHRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. CHRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.026) is normal, around the industry mean (2.936). P/E Ratio (0.000) is within average values for comparable stocks, (18.739). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.331). Dividend Yield (0.000) settles around the average of (0.228) among similar stocks. P/S Ratio (36.101) is also within normal values, averaging (141.748).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry InformationTechnologyServices